WEBULL
WebtradeDownload

Nektar Therapeutics (NKTR), What Is Drawing Fresh Attention Now?

Simply Wall St · 1d ago

Nektar Therapeutics (NKTR) moved on investor screens after fresh performance data sharpened interest in its immunotherapy pipeline, leaving traders weighing recent volatility against the firm’s clinical partnerships and ongoing autoimmune and oncology programs.

Recent trading has cooled some of the heat around Nektar Therapeutics, with the share price down 3.8% over the past week and 11.8% over 30 days. However, a 90 day share price return of 10.0% and a year to date gain of 54.5% signal that momentum, while choppy, remains positive in the broader context of a 21.7% one year total shareholder return and a very large 3 year total shareholder return driven by shifting expectations around its immunotherapy portfolio.

Scan for other immunotherapy and biotech names showing similar volatility and partnership-driven storylines by checking the hand picked 16 high quality undiscovered gems alongside Nektar Therapeutics.

Nektar Therapeutics has a busy pipeline and a long list of partners, and the share price has already reacted sharply. The real test now is whether that story is already fully reflected in today’s valuation.

Most Popular Narrative: 54% Undervalued

Nektar Therapeutics closed at $67.10 while the most followed narrative pegs fair value at $144.40. The gap investors are debating is large and built on a single high conviction pipeline story.

Robust cash position after the recent equity raise extends runway into 2027, providing operational stability to advance late-stage assets and initiate Phase III trials without near-term dilution or financing risk. This supports earnings predictability and reduces financial leverage concerns.

Broadening of pipeline applications (e.g., immunology, autoimmune, dermatology) and the prospect of international partnerships or strategic out-licensing align with the global expansion of healthcare access, providing opportunities for diversified and growing revenue streams in coming years.

See why 12 investors see Nektar Therapeutics as 54% undervalued.

Result: Fair Value of $144.40 (UNDERVALUED)

Still, the entire Nektar Therapeutics story leans heavily on Rezpeg trial execution and on a pre-commercial pipeline that continues to generate sizeable losses.

Find out about the key risks to this Nektar Therapeutics narrative.

Another View on Nektar Therapeutics Valuation

Analysts using a story driven fair value of $144.40 see Nektar Therapeutics as significantly undervalued. The market tells a different story. At a P/S of 42x, compared with an industry average of 5.3x and a fair ratio of 11.7x, the stock already prices in a lot of hope. Which signal do you trust more?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqCM:NKTR P/S Ratio as at Sep 2026
NasdaqCM:NKTR P/S Ratio as at Sep 2026

Next Steps

Mixed on Nektar Therapeutics after all this. If you want to move quickly and form your own stance, start with the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond Nektar Therapeutics?

Do not stop with Nektar Therapeutics when there are other opportunities on the move. Use the Simply Wall Street Screener now so you are not catching up later.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.